Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)A series of drug-like compounds derived from Sildenafil, Vardenafil and Tadalafil analogues were modelled through the MIA-QSAR (multivariate image analysis applied to quantitative structure-activity relationships) ligand-based approach. A highly predictive model was achieved and novel compounds, miscellany of substructures of these three representative phosphodiesterase type-5 (PDE-5) inhibitors were predicted using the calibration parameters obtained through partial least squares (PLS) regression. The high bioactivities of eight promising compounds were corroborated by docking evaluation. Calculated ADME-Tox (abs...
Tetrahydro-\u3b2-carboline derivatives (THBCs) have been identified as a class of potent Type-5 Phos...
This research project is concerned with the design, synthesis and development of new phosphodiestera...
The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treat...
In 1998, sildenafil was marketed as the first FDA-approved oral drug for the treatment of erectile d...
<p>The essential biological function of phosphodiesterase (PDE) type enzymes is to regulate the cyto...
[[abstract]]"Phosphodiesterase superfamily is the key regulator of 3′,5′-cyclic guanosine monophosph...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)A series of cyclic guanine derivatives,...
Two- and three-dimensional quantitative structure-activity relationship (QSAR) and docking studies w...
Great attention has been paid to the clinical significance of phosphodiesterase 5 (PDE5) inhibitors,...
[[abstract]]Erectile dysfunction (ED) is a sexual disorder mainly caused by decrease in cellular con...
Selective inhibitors of cyclic nucleotide phosphodiesterase-5 (PDE5) have been used as drugs for tre...
[[abstract]]Aim: To explore the potent inhibitor from one of the Traditional Chinese medicine (TCM),...
Objective: Prismatomeris memecyloides Craib (Rubiaceae) is a medicinal plant traditionally used by e...
[[abstract]]The traditional Chinese medicines (TCM), Epimedium sagittatum (ESs), Cnidium monnieri (C...
Orientadores: Gilberto De Nucci, Fabíola Taufic Mónica IglesiasTese (doutorado) - Universidade Estad...
Tetrahydro-\u3b2-carboline derivatives (THBCs) have been identified as a class of potent Type-5 Phos...
This research project is concerned with the design, synthesis and development of new phosphodiestera...
The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treat...
In 1998, sildenafil was marketed as the first FDA-approved oral drug for the treatment of erectile d...
<p>The essential biological function of phosphodiesterase (PDE) type enzymes is to regulate the cyto...
[[abstract]]"Phosphodiesterase superfamily is the key regulator of 3′,5′-cyclic guanosine monophosph...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)A series of cyclic guanine derivatives,...
Two- and three-dimensional quantitative structure-activity relationship (QSAR) and docking studies w...
Great attention has been paid to the clinical significance of phosphodiesterase 5 (PDE5) inhibitors,...
[[abstract]]Erectile dysfunction (ED) is a sexual disorder mainly caused by decrease in cellular con...
Selective inhibitors of cyclic nucleotide phosphodiesterase-5 (PDE5) have been used as drugs for tre...
[[abstract]]Aim: To explore the potent inhibitor from one of the Traditional Chinese medicine (TCM),...
Objective: Prismatomeris memecyloides Craib (Rubiaceae) is a medicinal plant traditionally used by e...
[[abstract]]The traditional Chinese medicines (TCM), Epimedium sagittatum (ESs), Cnidium monnieri (C...
Orientadores: Gilberto De Nucci, Fabíola Taufic Mónica IglesiasTese (doutorado) - Universidade Estad...
Tetrahydro-\u3b2-carboline derivatives (THBCs) have been identified as a class of potent Type-5 Phos...
This research project is concerned with the design, synthesis and development of new phosphodiestera...
The introduction of oral phosphodiesterase type 5 inhibitor therapy in 1998 revolutionized the treat...